This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-06 (NCT06024876),No investigational drug product will be administered in the study.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Frequency and severity of SAEs and CS-101 related AES as assessed by CTCAE v5.0
Timeframe: Through 15 years post CS-101 infusion
New malignancies and hematologic disorders
Timeframe: Through 15 years post CS-101 infusion
Occurrence of all-cause death
Timeframe: Through 15 years post CS-101 infusion
Occurrence of achieving transfusion independence for at least 12 consecutive months
Timeframe: Through 15 years post CS-101 infusion